Actinium Pharmaceuticals, Inc. Expands R&D Capabilities with New Research Facility to Enhance Development of Next Generation Antibody Radiation Conjugates Leveraging Its Proprietary AWE Platform PR Newswire NEW YORK, Oct. 14, 2020 NEW YORK, Oct. 14, 2020 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today announced the launch of its new research and development lab facility in New York City. This new research facility expands Actinium's internal R&D capabilities and will be focused on developing novel Antibody Radiation Conjugate (ARC) candidates, ARC therapeutic combination strategies, and supporting AWE platform research collaborations. Actinium's R&D efforts will employ a multidisciplinary approach leveraging its team's expertise and experience in cancer cell biology, radiochemistry, radiation sciences, immunology and oncology drug development. The proprietary AWE technology platform, protected by over one hundred and twenty-five patents, is the foundation for Actinium's R&D and exploits multiple different radioisotope payloads including the potent alpha-emitter, Actinium-225. (PRNewsfoto/Actinium Pharmaceuticals, Inc.) This new research facility will function under the guidance of Dr. Dale Ludwig, Ph.D. the Company's Chief Scientific & Technology Officer, who has over twenty-five years of oncology discovery research and development experience, including supporting the development and launch of Erbitux®, Cyramza^TM, Portrazza®, and Lartruvo^TM as well as the clinical advancement of at least 10 additional therapeutic antibodies and Antibody Drug Conjugates while at Eli Lilly and, previously, ImClone Systems Inc. The research facility will be managed and staffed by Ph.D. level scientists who will contribute their respective expertise in areas of drug discovery, radiation chemistry, and translational research to advance novel ARC programs and investigations into combination therapeutic strategies. "Our new research facility will allow us to significantly accelerate our preclinical and clinical development of novel ARC programs and investigate mechanistic ARC therapeutic combinations, which utilize our expertise in radioimmunobiology, our AWE Technology Platform capabilities,
CEO at Urjanet, helping organizations impact people, planet and profits using our innovative cloud-based data service.
Digital transformation in banking and lending has been underway for several years, but the pace is accelerating as a result of the Covid-19 pandemic. As banks pivot from branch footprint expansion to an omni-channel strategy, the truly digital customer experience is finally here.
To be competitive throughout the pandemic and after it, building a customer-focused, digital-first institution is a must as customer-centric banks outperform their more traditional peers. Investments in data innovation can help streamline this shift to online experiences and also yield substantial returns. One study showed that banks and credit unions that digitize processes can achieve a 20% increase in revenues and a 30% decline in expenses.
This requires not just financial services institutions but also their partners and suppliers to rethink how they leverage data and technology. My own company has had to refocus our product roadmap, service model and support tools for our financial services customers in light of the Covid-19 pandemic to deliver better digital processes. Corporately, we’ve also had to adjust how we interact with banking and lending customers, most recently shifting our annual customer conference from an in-person event in Atlanta to a series of digital events. In September, we met virtually with these industry leaders and their solution providers to hear how they are adapting to the new global circumstances with data innovation and new customer experiences.
Consumers demand simple, trustworthy experiences from financial institutions.
Customers’ expectations are rising when it comes to banking and data privacy. According to EY’s customer research, only 60% of consumers are comfortable sharing personal information with their primary financial service provider without any assurance regarding data protection and security. Features like full price transparency, hyper-personalization and clear ownership